Global Patent Index - EP 2037890 A1

EP 2037890 A1 20090325 - ORAL PHARMACEUTICAL COMPOSITION OF A POORLY WATER-SOLUBLE ACTIVE SUBSTANCE

Title (en)

ORAL PHARMACEUTICAL COMPOSITION OF A POORLY WATER-SOLUBLE ACTIVE SUBSTANCE

Title (de)

ORALE PHARMAZEUTISCHE ZUSAMMENSETZUNG EINER SCHWER WASSERLÖSLICHEN WIRKSUBSTANZ

Title (fr)

COMPOSITION PHARMACEUTIQUE À ADMINISTRATION PAR VOIE ORALE CONTENANT UN PRINCIPE ACTIF PEU SOLUBLE DANS L'EAU

Publication

EP 2037890 A1 20090325 (EN)

Application

EP 07730293 A 20070621

Priority

  • EP 2007056207 W 20070621
  • US 81557906 P 20060622
  • EP 06115881 A 20060622
  • IN 1473DE2006 A 20060622
  • EP 07730293 A 20070621

Abstract (en)

[origin: WO2007147873A1] Provided in the present invention are improved oral pharmaceutical compositions comprising at least one poorly water soluble active agent, preferably endothelin conversion enzyme (ECE) inhibitor and/or neutral endopeptidase (NEP) inhibitor in an amount greater than 10% w/w of the composition, more preferably, with the alkali system co mprising a mixture of at least two alkaline compounds in the ratio 1:20 to 20:1, the active agent is SLV-306 or its pharmaceutically acceptable salts, esters, hydrates, solvates, isomers or derivatives thereof; a alkali system in an amount greater than 10% w/w of the composition preferably comprising a mixture of at least two alkaline compounds and optionally one or more pharmaceutically acceptable excipients. Also provided are process for preparation of such improved compositions and method of using such composition.

IPC 8 full level

A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 31/55 (2006.01); A61K 45/08 (2006.01)

CPC (source: EP KR)

A61K 9/20 (2013.01 - KR); A61K 9/2009 (2013.01 - EP); A61K 9/485 (2013.01 - EP); A61K 31/55 (2013.01 - KR); A61P 7/04 (2017.12 - EP); A61P 9/00 (2017.12 - EP); A61P 9/04 (2017.12 - EP); A61P 9/08 (2017.12 - EP); A61P 9/10 (2017.12 - EP); A61P 9/12 (2017.12 - EP); A61P 43/00 (2017.12 - EP)

Citation (search report)

See references of WO 2007147873A1

Citation (examination)

WO 2006067150 A1 20060629 - SOLVAY PHARM BV [NL], et al

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

Designated extension state (EPC)

AL BA HR MK RS

DOCDB simple family (publication)

WO 2007147873 A1 20071227; AU 2007263016 A1 20071227; CA 2654243 A1 20071227; EA 200970045 A1 20090630; EP 2037890 A1 20090325; IL 195653 A0 20090901; JP 2009541267 A 20091126; KR 20090033246 A 20090401; NO 20090265 L 20090122

DOCDB simple family (application)

EP 2007056207 W 20070621; AU 2007263016 A 20070621; CA 2654243 A 20070621; EA 200970045 A 20070621; EP 07730293 A 20070621; IL 19565308 A 20081202; JP 2009515884 A 20070621; KR 20097001506 A 20090122; NO 20090265 A 20090116